

Title: Colchicine and COVID-19

Pablo Corral, MD.

Departamento de Investigacion, Facultad de Medicina, Universidad FASTA, Buenos Aires, Argentina

Gonzalo Corral, MD

Servicio de Infectología Clínica 25 de Mayo; Servicio de Infectología, HIGA Alende, Mar del Plata, Buenos Aires, Argentina

Rafael Diaz, MD

Estudios Cardiológicos Latinoamérica, Instituto Cardiovascular de Rosario, Rosario, Argentina

Total word count: 195

Funding: none

Disclosures:

Pablo Corral: reports honoraria for lectures from Amgen, Sanofi, AstraZeneca and PTC; research grants from Amgen and Genzyme and personal fees for consultancy from Amgen, Novartis and Sanofi.

Rafael Diaz: reports research grants from Sanofi, DalCor, Population Health Research Institute, Duke Clinical Research Institute, the TIMI group, Amgen, Cirius, Montreal Health Innovations Coordinating Center, and Lepetit; and personal fees from Amgen and Cirius

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the [Version of Record](https://doi.org/10.1002/jcph.1684). Please cite this article as [doi: 10.1002/jcph.1684](https://doi.org/10.1002/jcph.1684).

This article is protected by copyright. All rights reserved.

Address for correspondence

Dr. Pablo Corral

Rawson 1006, Mar del Plata, Buenos Aires, Argentina, zip 7600

drpablocorral@gmail.com

Acknowledgements: none

Colchicine and COVID-19

We have read with interest the Letter to the Editor entitled “Can Colchicine as an Old Anti-Inflammatory Agent Be Effective in COVID-19?” by Somayyeh Nasiripour et al. (1), in which the authors stated that only one phase 3, multicenter, randomized, double-blind, placebo-controlled multicenter study has been assigned to clinicaltrials.gov by Montreal Heart Institute, to investigate the efficacy and safety of colchicine in adult patients diagnosed with COVID-19 (2).

In Argentina, we started COLCOVID Trial, in order to test the effects of colchicine on moderate/high-risk hospitalized COVID-19 patients with the aim of reducing mortality. This study is a phase 3, multicenter, controlled trial; our protocol was published in [ClinicalTrial.gov](https://clinicaltrials.gov) on March 31, 2020 (3).

Therefore, we would like to affirm that, besides the COLCORONA Trial, there is another study ongoing focused on Colchicine in COVID-19.

We appreciate the opportunity to express our comment following the recent publication of the potential role of the Colchicine in SARS-CoV-2 infection.

References

- 1- Nasiripour S, Zamani F, Farasatinasab M. Can Colchicine as an Old Anti-Inflammatory Agent Be Effective in COVID-19? [published online ahead of print, 2020 May 23]. J Clin Pharmacol. 2020;10.1002/jcph.1645. doi:10.1002/jcph.1645
- 2- <https://clinicaltrials.gov/ct2/show/NCT04322682>
- 3- <https://clinicaltrials.gov/ct2/show/NCT04328480>